We have reported previously a new method for detecting thyroglobulin release stimulating activity (Tg-RSA) by human thyroid monolayer cells in IgGs from Graves' patients. We report here changes in Tg-RSA in sera of patients during treatment with thionamide drug.
We have previously reported that thyroglobulin release stimulating activity (Tg-RSA) in immunoglobulin G(IgG) from untreated Graves' patients with hyperthyroidism can be a new indicator of abnormal stimulators in the sera of the patients (Fukue et al., 1987) . A variety of thyroid autoantibodies have been demonstrated in the circulation of patients with Graves' disease, and thyroid simulating IgG which is directed against determinants closely related to the TSH-receptor site(s) has elicited deep interest and is widely thought to be involved in causing hyperfunction of the thyroid (McKenzie et al., 1978; Burman and Baker, 1985) .
Methods hitherto used in detecting the stimulating activity include cellular Na 131I uptake (Kasagi et al., 1988) , stimulation of cyclic AMP accumulation (Hins et al., 1981) , radioiodine or T3 release (Atkinson et al., 1982; Atkinson and Kendal-Taylor, 1981) and colloid droplet formation (Onaya et al., 1973) , using thyroid slices or cultured cells and inhibition of TSH-binding (Smith and Hall, 1947 ) using thyroid plasma membrane. Although activities assayed by these methods for Graves' IgG have been shown to decrease gradually during antithyroid drug treatment (Teng and Yeung, 1980; Bech and Madesen 1980; Karlsson and Dahlberg, 1981) there is no report which deals with the paired determinations of Tg-RSA and other indicators during the therapy to compare with each other. Tg is a thyroid specific protein and the secretion from thyroid cells is a final functional response in vitro and in vivo (Izumi and Larsen, 1978; Fukue et al., 1987) . Tg-RSA, which measures the activity of Tg release from human thyroid monolayer cells in IgG from Graves' patients, has been confi rmed to be correlated with the TSAb and serum Tg concentrations.
In order to clarify the properties of Tg-RSA we have studied changes in Tg-RSA in the IgG sample taken from Graves' patients before and during thionamide drug therapy. An attempt was also made to correlate the changes in Tg-RSA and Tg concentrations in sera during the therapy. abnormal stimulator in the patients' sera (Fukue et al., 1987 
